Biological immunosuppressants: the way to clinical transplantation tolerance.
Chatenoud
L
L
Inserm U25, Hôpital Necker, Paris, France.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006085:Graft Survival / Q000187:drug effects / Q000276:immunology; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology; D008213:Lymphocyte Activation; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D014181:Transplantation Immunology; D014184:Transplantation, Homologous / Q000276:immunology*
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3